2024-513662-18-00
Recruiting
Phase 1/2
A phase 1/2, open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) in patients with retinitis pigmentosa due to monogenic mutation
Centre D'Etude Des Cellules Souches1 site in 1 country12 target enrollmentStarted: June 12, 2024Last updated:
Overview
- Phase
- Phase 1/2
- Status
- Recruiting
- Sponsor
- Centre D'Etude Des Cellules Souches
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Safety and tolerability measured by the incidence of adverse events (AE) or serious adverse events (SAE) evaluated by changes in ophthalmologic exams, laboratory parameters, vital signs and in the physical examination from baseline to each visit, will be evaluated for each patient over 56 weeks.
Overview
Brief Summary
To assess safety and tolerability of implantation of the IMP (ISTEM-01) in patients with retinitis pigmentosa over 56 weeks after IMP implantation.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Documented diagnosis of retinis pigmentosa based on a genetic test confirming the presence of a monogenic mutation that affects a gene involved in the visual signalling process specifically at the level of RPEs, namely RPE65 or LRAT, or MerTK
- •18 years old ≤ Age ≤ 65 years old
- •During the SARS-Cov-2 pandemic period, patient negative to SARS-CoV-2 (PCR or any new test validated)
- •For patient of the first cohort: Visual acuity ≤ 20/200 in the best eye (legally blind). For patient of the second cohort: 20/63 > Visual acuity > 20/800 in the worst eye And Visual field exceeding 10° central to the V4 test in the worst eye And Visible photoreceptor outer nuclear layer (ONL) on a spectral domain optical coherence tomography (OCT) scan
Exclusion Criteria
- •History of allergy or sensitivity to one of the products used during the study
- •Prior treatment with a gene or cell therapy product
- •Patients with preformed anti-HLA antibodies against the human Embryonic Stem Cell (hESC) line RC9 with MFI > 2000 or patients with intermediate MFI values (between 500 and 2000) at screening associated to medical history of clinical significance, according to expert’s opinion
- •Presence of any ocular disease or ocular media opacity which in the opinion of the investigator precludes accurate evaluation
- •Patients treated with Luxturna®
- •Systemic corticosteroid therapy or other immunosuppressive/ immunomodulating or anti-retroviral drugs within 2 months prior to baseline
Outcomes
Primary Outcomes
Safety and tolerability measured by the incidence of adverse events (AE) or serious adverse events (SAE) evaluated by changes in ophthalmologic exams, laboratory parameters, vital signs and in the physical examination from baseline to each visit, will be evaluated for each patient over 56 weeks.
Safety and tolerability measured by the incidence of adverse events (AE) or serious adverse events (SAE) evaluated by changes in ophthalmologic exams, laboratory parameters, vital signs and in the physical examination from baseline to each visit, will be evaluated for each patient over 56 weeks.
Secondary Outcomes
- Placement and position of the therapeutic patch by serial spectral domain Ocular Coherence Tomography (OCT) scan at Baseline, and by study visit
- Change in leakage or perfusion in normal fundal vasculature and presence of abnormal vasculature by fundus fluorescein angiography at Baseline, weeks 24 and 56 and yearly during the long-term follow-up study.
- Change in thickness of RPE layer by B-mode orbital ultrasound at Baseline, weeks 24, and 56 and yearly during the long-term follow-up study.
- Change in eye exam and IntraOcular Pressure (IOP) from baseline, and by study visit
- Change in ETDRS/ best corrected visual acuity (BCVA) from baseline and by study visit
- Change in kinetic perimetry from baseline, at weeks 4, 8, 12, 24, 36, 48 and 56 and yearly during the long-term follow-up study.
- Evidence of retinal and RPE functionnality by global, pattern and multifocal ERG at baseline and week 56 and yearly during the long term follow-up period
- Functional survival of retinal photoreceptors by microperimetry over hESC-derived RPE at weeks 4, 8, 12, 24, 36, 48 and 56 and yearly during the long term follow-up period
Investigators
General Manager
Scientific
Centre D'Etude Des Cellules Souches
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 2
Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt’s Macular Degeneration2024-513501-31-00Sanofi-Aventis Recherche & Developpement14
Recruiting
Not Applicable
Phacoemulsification and Intraocular Lens Implantation: Patient RegistryNCT07276217Sensor Cliniq300
Active, not recruiting
Phase 3
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents2024-512837-34-00Teva Branded Pharmaceutical Products R&D LLC249
Completed
Not Applicable
Clinical trial of chronically implanted retinal prosthesis by Suprachoroidal-Transretinal Stimulaiton in patient with retinitis pigmentosaretinitis pigmentosaJPRN-UMIN000012754Department of Applied Visual Science, Osaka University Graduate School of Medicine3
Recruiting
Not Applicable
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001NCT07264569Henan Cancer Hospital42